Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity

Area of Science:

• Neuropharmacology
• Behavioral Neuroscience

Background:

• Chronic haloperidol treatment in rats leads to behavioral hypersensitivity (BH).
• This BH is hypothesized to result from increased dopamine (DA) receptor numbers after chronic pharmacologic denervation.

Purpose of the Study:

• To investigate if cotreatment with various agents can prevent or reduce the development of BH during chronic haloperidol administration.
• To elucidate the role of dopamine biochemistry and receptor changes in the development of BH.

Main Methods:

• Laboratory rats underwent chronic haloperidol treatment.
• Cotreatment strategies were employed using agents like lithium, amantadine, thioridazine, and scopolamine.
• Dopamine biochemistry and DA receptor numbers were assessed.

Main Results:

• Lithium and amantadine cotreatment prevented both DA biochemical alterations and DA receptor proliferation associated with chronic haloperidol.
• Thioridazine and scopolamine altered DA biochemistry but did not prevent DA receptor proliferation or BH.
• DA receptor proliferation appears permissive, but not solely causative, for BH development.

Conclusions:

• Mechanisms beyond dopamine receptor changes contribute to the development and expression of behavioral hypersensitivity.
• Dopamine receptor proliferation is a necessary but insufficient factor for the full development of BH.
• Cotreatment strategies offer insights into modulating neurochemical adaptations and behavioral responses to antipsychotic medications.